How to Get Insurance to Cover Wegovy: Prior Authorization Tips That Actually Work in 2026

The $1,349 Question Nobody Wants to Ask

Your doctor just prescribed Wegovy. You're cautiously optimistic. Then the pharmacy calls: "Your insurance denied it. That'll be $1,349.02."

This scene is common in the United States. GLP-1 medications like Wegovy sit in a strange coverage limbo—FDA-approved, clinically proven, yet treated by many insurers and employer plans as optional.

But a first denial isn't always the end. In a 2026 JAMA Health Forum study of 2024 pharmacy claims for branded drugs initially rejected for prior authorization, 54% were eventually approved—though most patients faced delays. Documentation and knowing how the process works make a real difference.

Why Insurers Keep Saying No (And What Changed in 2026)

Insurance companies aren't cartoon villains. GLP-1 medications are expensive and often used long term, so plans and employers use tools like prior authorization, step therapy and BMI criteria to control spending.

The most common denial reasons break down like this:

• "Not medically necessary"
• "Step therapy required"—meaning you haven't tried cheaper options first
• "BMI criteria not met"
• "Missing documentation"
• "Excluded benefit"—the plan doesn't cover weight-loss drugs at all

The 2026 landscape did shift. By law, Medicare Part D has generally excluded drugs used for weight loss, although Part D plans could cover Wegovy for its cardiovascular risk-reduction indication. Under CMS's BALANCE Model, state Medicaid programs could start covering GLP-1s for weight management as early as May 2026, and since July 1, 2026, eligible Part D beneficiaries can get certain GLP-1s, including Wegovy, through the Medicare GLP-1 Bridge for a $50 copay (running through December 31, 2027). Commercial coverage, meanwhile, still varies widely by insurer and employer.

But "expanded" doesn't mean "easy." It means the goalposts moved, not disappeared.

The Prior Authorization Playbook: Step One

Before your doctor submits anything, you need intelligence. Call your insurance company's pharmacy benefits line (not general customer service—they won't know) and ask these exact questions:

1. What specific BMI threshold triggers coverage eligibility?
2. Which comorbidities qualify as "weight-related conditions"?
3. What prior treatments must be documented, and for how long?
4. Is there a preferred GLP-1 on formulary that might face fewer barriers?

Write down the representative's name, the call reference number, and the date. This matters later.

Most plans follow the FDA label: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. But details differ. Some plans accept a documented BMI history, while others want a measurement taken within a recent window, and some specify who must record it.

These details live in your plan's clinical policy bulletin, usually findable by searching "[insurer name] GLP-1 clinical policy" online. Read it like a lawyer. It's boring. Do it anyway.

Building Your Documentation Arsenal

The prior authorization form your doctor fills out is just the cover letter. The real work happens in the supporting documentation.

Your packet should include:

Weight history documentation: At minimum, 6 months of recorded weights showing your BMI meets criteria. Twelve months is stronger. If your weight fluctuates, include the dates when it was highest—insurers don't average, they look for qualifying snapshots.

Comorbidity evidence: Lab results, imaging reports, or specialist notes confirming conditions like type 2 diabetes, hypertension, sleep apnea, or osteoarthritis. A diagnosis code alone often isn't enough; many plans ask for supporting clinical records.

Failed intervention records: Documentation of previous weight loss attempts. This typically means 3-6 months of a structured program—physician-supervised diet, registered dietitian visits, or a commercial program like WW with attendance records. Gym memberships don't count. "I tried eating less" definitely doesn't count.

Letter of medical necessity: Your physician writes this, but you can help draft it. The letter should connect your weight to specific health risks, explain why Wegovy specifically (not just any intervention) is appropriate, and reference clinical trial data.

A weak letter says: "Patient has obesity and would benefit from Wegovy."

A strong letter says: "Patient has Class II obesity with a BMI of 36.2, documented hypertension requiring two medications, and prediabetes with HbA1c of 6.1%. Despite completing a 16-week medically supervised diet program resulting in only 4% body weight reduction, her cardiovascular risk remains elevated. The STEP 1 trial demonstrated 14.9% mean weight reduction with semaglutide, which would significantly reduce her hypertension medication requirements and diabetes progression risk."

See the difference? Numbers. Specificity. Clinical trial references. Cause and effect.

When They Say No: The Appeals Process That Works

Your denial arrives. Don't panic. Don't accept it.

Under the ACA, you generally have 180 days (6 months) from the denial notice to file an internal appeal, and for a treatment you haven't received yet, the insurer must decide within 30 days. Medicare plans follow their own appeal rules. Check your denial letter for the exact deadline—missing it usually means starting over.

There's no reliable public figure for GLP-1-specific appeal success rates, and outcomes vary by plan. What helps most is an appeal that answers the stated denial reason directly.

Your appeal letter needs to directly address the stated denial reason. If they said "step therapy not completed," provide documentation of the alternatives you tried. If they said "not medically necessary," add more clinical evidence and peer-reviewed studies.

Consider asking that the appeal be reviewed by a physician with relevant expertise—endocrinology, obesity medicine, or internal medicine. Plans differ in who reviews appeals, and the request signals that the clinical details matter.

The appeal packet should contain everything from the original submission plus:

• A cover letter specifically addressing the denial reason
• Any new clinical documentation
• Peer-reviewed studies supporting GLP-1 use for your specific situation
• A timeline showing your treatment history

Submit via certified mail or the insurer's secure portal with delivery confirmation. Keep copies of everything.

External Review: Your Nuclear Option

Internal appeal denied? You now have access to external review—an independent third party evaluates your case. This is federally mandated for most health plans under the ACA.

Public data on GLP-1-specific outcomes are limited, but external review matters for a simple reason: if the independent reviewer sides with you, the plan must accept the decision.

External reviewers aren't employed by your insurer. They work for independent review organizations and evaluate your case on its clinical merits and your plan's terms.

To request external review, file a written request within 4 months of receiving the final internal denial. Your denial letter should explain how, and whether your plan uses a state or the federal process.

The external reviewer receives your complete file and typically issues a decision within 45 days—or 72 hours if your physician certifies the situation as urgent.

State Laws That Might Help You

Insurance regulation happens largely at the state level, and the rules change often. Some states have passed laws limiting step therapy, and a few require coverage of obesity treatment in certain plans—while some state Medicaid programs and state employee plans have cut back GLP-1 coverage for weight loss because of cost.

Your state insurance department or consumer assistance program can tell you which rules apply to your plan.

These state laws generally apply only to fully insured plans (where your employer buys coverage from an insurer). Self-funded employer plans—common at large companies—are regulated federally under ERISA, so state mandates usually don't apply.

Not sure which type you have? Your plan documents will say, or you can ask HR directly.

The Employer Backdoor

Here's something most people don't try: talking to their employer's benefits team.

Large employers often have flexibility in their plan design. If multiple employees are requesting GLP-1 coverage, some employers add it at annual renewal—weighing the cost against potential long-term health benefits.

You don't need to share personal health information. Simply ask: "Has the company considered adding GLP-1 medication coverage to our pharmacy benefits? I understand several employees have expressed interest."

Some employers have created carve-out programs specifically for weight management medications, often with requirements like participation in coaching programs or health assessments. It's not ideal, but it's coverage.

What to Do While You Wait

Appeals take time. Weeks, sometimes months. What happens to your treatment in the meantime?

Some options to discuss with your doctor:

Manufacturer savings programs: As of October 2026, Novo Nordisk lists a savings offer for commercially insured patients whose plan covers Wegovy (as little as $25 a month, with maximum savings of $100 a month; government beneficiaries excluded). Without coverage, NovoCare Pharmacy self-pay pricing is $349 a month for most Wegovy pen doses, with lower introductory prices for new patients. Terms change often, so check the manufacturer's site.

Compounded semaglutide: The FDA's semaglutide shortage ended in 2025, which sharply limited legal compounding of copies. Even so, a 2026 JAMA Health Forum study found weight-loss clinics still offering compounded GLP-1s, often with added ingredients, sourced in some cases from facilities not licensed for sterile compounding. Discuss the risks with your physician.

Alternative GLP-1s: If your plan covers Zepbound (tirzepatide) or Saxenda (liraglutide) more readily, these might be options while you appeal for Wegovy specifically.

Telehealth weight management programs: Some programs bundle clinician visits with prescriptions for a monthly fee. Check exactly which medication is prescribed (brand-name or compounded), what's included, and whether the program helps with insurance paperwork.

The Persistence Tax

Let's be honest about what this process demands. You'll spend hours on phone calls. You'll read dense policy documents. You'll write letters and gather records and wait for responses that take too long.

This is, effectively, a tax on people seeking treatment for a chronic disease. It's not fair. Research on prior authorization across branded drugs shows that most patients whose prescriptions are initially rejected face delays, and many are ultimately denied.

Knowing that might not make the process easier, but it might make you angrier. Sometimes anger is useful fuel.

Document everything. Appeal every denial. Request external review. Contact your state insurance commissioner if you believe your plan is violating coverage laws.

The system is designed to make you give up. Don't.